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Structure-Activity Relationships in Purine-Based
Inhibitor Binding to HSP90 Isoforms
contain a binding site for novobiocin [4, 5]. The structure
of the middle domain for the yeast homolog of HSP90
has been determined recently [6]. This displays a large
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The N-terminal domain of HSP90 provides all of the
structural requirements for nucleotide binding. How-Inhibition of the ATPase activity of the chaperone pro-
ever, it alone has relatively little ATPase activity, andtein HSP90 is a potential strategy for treatment of can-
contacts from the middle domain of full-length HSP90cers. We have determined structures of the HSP90
are also required to ensure functionality of the enzyme.N-terminal domain complexed with the purine-based
The catalytic residues Arg 380 and Gln 384 are contrib-inhibitor, PU3, and analogs with enhanced potency
uted by the middle segment of HSP90, and both in vitroboth in enzyme and cell-based assays. The com-
and in vivo studies have confirmed their essentialpounds induce upregulation of HSP70 and downregu-
involvement in ATPase activity and chaperone function.lation of the known HSP90 client proteins Raf-1, CDK4,
The “catalytic loop” bearing Arg 380 and Gln 384 showsand ErbB2, confirming that the molecules inhibit cell
significant flexibility, varying between a helical structuregrowth by a mechanism dependent on HSP90 inhibi-
where these residues are directed out of the ATP bindingtion. We have also determined the first structure of
site to an extended loop in which they could reach intothe N-terminal domain of HSP90, complexed with
the ATP binding site and interact with bound ATP [6].PU3. The structures allow a detailed rationale to be
The HSP90 ATPase activity can be selectively inhib-developed for the observed affinity of the PU3 class
ited by natural product antibiotics such as geldanamycinof compounds for HSP90 and also provide a structural
or radicicol [1]. Recent studies with geldanamycin deriv-framework for design of compounds with improved
atives suggest that cancer cells are particularly sensitivebinding affinity and drug-like properties.
to HSP90 inhibition, inducing cell cycle arrest and apo-
ptosis. Although the exact mechanism for the tumor cell
Introduction selectivity of these natural products has yet to be fully
elucidated, the most compelling suggestion is a tumor
HSP90, HSP90, GRP94, and TRAP-1 are members of cell dependence on key signaling proteins that are cli-
a highly abundant family of human chaperones respon- ents of the HSP90 family of chaperones. Exposure to
sible for the maturation and activity of a variety of key HSP90 inhibitors results in depletion of a number of
client proteins involved in cell growth and proliferation oncogenic client proteins, including Raf-1, ErbB2, Akt/
(see [1], [2], and references therein). PKB, CDK4, Met, POLO-1, mutant p53, and the andro-
HSP90 function is ATP dependent and an intrinsic gen/estrogen receptors. A particular therapeutic ad-
ATPase activity is required for the operation of a func- vantage of HSP90 inhibitors may result from their simul-
tional “chaperone” cycle, which leads to the stabilization taneous combinatorial effects on multiple oncogenic
of client proteins [3]. It is thought that all of the HSP90 proteins and pathways that are responsible for driving
family members have a similar mode of action but act malignant progression [1, 2]. The radicicol and geldana-
on different client proteins dependent, in part, on their mycin natural product classes of HSP90 inhibitors have
localization within the cell [1]. significant limitations, for example, with respect to
The HSP90 proteins have three domains. The C-ter- ADME properties [1]. The development of improved,
minal domain is the site for homodimerization of the synthetic inhibitors is therefore an important objective.
proteins and contains binding sites for cochaperones. Chiosis et al. have described the design of a series
This domain has recently been shown to be important of purine analogs (the lead molecule being PU3, com-
for autophosphorylation of the protein and may also pound 1) and measured binding affinity and cellular ac-
tivity [10, 11]. We have recently published an initial report
on the design of PU3 analogs with enhanced activity in*Correspondence: r.hubbard@vernalis.com
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Figure 1. Structures of Nt-HSP90 Isoforms
(A) Comparison of the structure of some apo-
Nt-HSP90 proteins. The proteins are overlaid
on all main chain atoms except for residues
104–111, which are colored in yellow for the
tetragonal form of yeast HSP90 (PDB ID code
1AH6), red for orthorhombic form of yeast
HSP90 (1AH8), green for human HSP90
(1YES), and purple for the apo-Nt-HSP90
structure reported here. This figure (and Fig-
ures 4 and 6) was produced using QUANTA
(Accelrys, San Diego).
(B) Comparison of apo (yellow) and PU3
bound (light blue) Nt-HSP90 highlighting the
secondary structure (wider ribbons) and PU3
(in green stick). This figure (and [C] and Figure
3) was produced using ViewerPro (Accelrys,
San Diego).
(C) The structure of human Nt-HSP90 with
PU3 bound (green stick). Amino acid differ-
ences between HSP90 and HSP90 are
shown in yellow.
both enzyme and cell-based assays [12]. Here, we report tion, whereas, in other yeast and some human struc-
tures, this helix unwinds to form an “open” conforma-the structures of Nt-HSP90 complexed to a series of
PU3 analogs and demonstrate how a detailed analysis tion. In the Nt-HSP90 structure reported here, this
region unwinds to form a loop that extends over theof the structures provides a rationale of the observed
changes in activity of these and the previously reported binding site, effectively closing it. These comparisons
demonstrate that there is considerable plasticity in thisPU3 analogs. In addition, we report the first determina-
tion of the structure of the homologous Nt-HSP90 region of the structure, which is at the entrance to the
ATP binding site. Some of the residues seen as impor-bound to the inhibitor PU3.
tant for binding to ligands are in this loop, e.g., Leu 107.
Results and Discussion
Structure of Nt-HSP90 in Complex with PU3
Figure 1B compares the structure of Nt-HSP90 deter-Structure of Apo-Nt-Human HSP90
We have independently determined and refined the mined from crystals grown in the presence and absence
of the compound PU3, and Figure 2 shows a schematicstructure of human apo-Nt-HSP90 at 1.42 A˚ resolution
in the presence and absence of an N-terminal hexa- representation of the interactions made between PU3
and the protein binding site. The ligand sits in the ADPhistidine tag. The structures are essentially identical to
the “closed” conformation for the protein described by binding site with essentially no change in conformation
across most of the protein structure. However, the re-Stebbins et al. ([8]; Protein Data Bank [PDB] ID code
1YER), and no density can be observed for the tag. gion 104–111 adopts a helical conformation, providing
space for binding of the trimethoxy phenyl moiety ofFigure 1A shows a comparison of our structure with
other published apo forms of human Nt-HSP90 and PU3. This change in conformation of the helix introduces
a channel through the protein running from the ATPyeast Nt-HSP90. The main variation between structures
is in the conformation of residues 104 to 111. In some binding site behind the helix and out to solvent. It is
mainly hydrophobic in nature, although three water mol-yeast structures, this region adopts a helical conforma-
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Figure 2. PU3 Binding to HSP90
Schematic of interactions between PU3 and the binding site of Nt-HSP90 (figure produced using Ligplot, [32]).
ecules do sit in the channel, making hydrogen bonds and reproducible than for Nt-HSP90, so all subsequent
work has been conducted with the  isoform.with one of the methoxy groups of the PU3 ligand and
with various residues within the channel.
Comparison of Ligand Binding
Figure 3 shows the detail of the binding sites of Nt-Human Nt-HSP90 in Complex with PU3
Figure 1C shows the structure of Nt-HSP90 with PU3 HSP90with PU3, ADP [13], geldanamycin [8], and radi-
cicol [14] bound. The key interactions with Asp 93 arebound. The overall structures of  and  are essentially
identical (rmsd 0.39 A˚ when overlapped on all main chain preserved in all complexes, with a network of hydrogen
bonds around the carboxylate of Asp93 involving Asn51,atoms), and the same changes are seen in the conforma-
tion of loop 104–111. The majority of residues that differ Ser52, Thr284, Gly97, and four water molecules consis-
tently found in the same positions. Three of these watersin sequence between the two isoforms are located
within the  sheet on the opposite side of the molecule are hydrogen bonded to ADP, PU3, and geldanamycin,
while radicicol interacts with two waters and displacesfrom the binding site (highlighted in yellow). Only one
residue (Val144) is close to the ligand, but the side chain a third one. The important role played by the crystallo-
graphic waters in the recognition of the ligands byis facing away from the binding site. In our hands, pro-
duction and crystallization of Nt-HSP90 is more rapid HSP90 is further supported by the almost identical local-
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Figure 3. Binding of Ligands to Nt-HSP90
Key protein residues and water molecules shown for ADP (from PDB ID code 1BYQ, human), PU3 (this paper), geldanamycin (1YET, human),
and radicicol (1BGQ, yeast). In addition, the PU3 panel includes an Fo-Fc electron density map contoured at 2.8 , calculated for the final
refined structure with PU3 omitted. Carbon atoms for the protein are in dark gray and for ligand in light yellow. Oxygen atoms are red, nitrogen
blue, sulfur yellow, and phosphorus orange. Water molecules are shown as small red spheres. Note that the equivalent residue to Leu 107 in
human HSP90 is Asn in yeast.
ization of these water molecules across all the structures of HSP90, and so it is not surprising that the previously
available so far. predicted binding mode was incorrect. The new channel
Most of the van der Waals contacts established be- has striking chemical complementarities for the ligand,
tween the ligands and the residues defining the cavity as seen in Figure 2. The aromatic ring of PU3 is stacked
around Asp93, namely Asn51, Ser52 (Ala38 in yeast), between the side chains of Phe138 and Leu107 and
Ala55, Met98, and Thr184, are also conserved, but fur- forms other favorable hydrophobic interactions with
ther away from Asp93 the interactions are less con- Met98 (S) and Leu103 (C2). In addition, the methyls
served. For instance, the Mg2 ion seen in ADP-bound of the methoxy groups make favorable hydrophobic
structures is not required for the binding of other ligands, contacts with the aromatic rings of Trp162 and Tyr139
and polar interactions with groups such as N of Lys58, as well as with the aliphatic carbons of Ala111 and
N of Lys112, and N of Phe138 are ligand specific. Val150. The only residues in the binding site that change
conformation are those in the flexible helix, while
Phe138, Met98, Val150, Trp162, and Tyr139 remain inThe PU3 Binding Mode
the same conformation. The end of the channel is morePU3 was designed with a purine ring to mimic the ade-
hydrophilic, lined with polar atoms from Leu103 (O),nine of ADP/ATP and a trimethoxy phenyl ring to reach
Trp162 (N), Tyr139 (O), and Gly108 (N). These maintaintoward the phosphate binding region of the ATP binding
a network of water molecules that can interact with thesite [10]. From our structures, it can be seen that the
oxygen atoms of the methoxy groups in R4 and R5.purine ring of PU3 does bind in the same position as
The alkyl chain at N9 of PU3 is located in the samethat of ADP (rmsd  0.5 A˚). However, the formation
position as the ribose of ADP, but the exit from theof a helix by residues 104–111 creates a channel that
binding pocket has a different shape in the two com-accommodates the trimethoxy phenyl ring of the ligand.
plexes. In particular, Leu107 is displaced by approxi-Chiosis et al. used the “open” structure of HSP90 (PDB
mately 4 A˚, blocking the space in the direction of theID code 1YET) to manually dock PU3 in the ATP binding
N9-R	bond in the PU3 complex. At either side of Leu107,site, and protein flexibility was only considered by mini-
Met98 and the phenyl ring of PU3 are also limiting themization of the resulting complex [10]. Our structures
space available for N9 substituents. As a result, thisshow that PU3 induces a conformational change that
transforms the shape of the phosphate binding region position is more impeded for PU3 than for ADP binding.
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Figure 4. Purine Analogs and Enzyme Inhibition Data
Both the amino acid composition and the shape of PU3 and 8 the most active published PU3 analog [11],
where the affinity of PU3 for HSP90 was measured bythe Bergerat fold are well conserved within the GHKL
superfamily [9]. This structural similarity allows cross- an immobilised geldanamycin displacement assay (a
binding assay). In our study, the activity of the com-reactivity, as shown by the strong inhibition of branched-
chain -keto acid dehydrogenase kinase by radicicol pounds has been measured as IC50 for inhibition of the
ATPase activity of full-length yeast HSP90 based on a[15]. The residues that line the new channel do not show
any significant sequence or structural homology with malachite green assay [16]. For comparison, PU3 (1) is
not active in the ATPase assay (
200 M), whereasother members of the GHKL superfamily (data not
shown), suggesting a route to specific HSP90 inhibitors. it is 15–20 M in the binding assay. The most potent
compound of Chiosis et al. (8) is 30 M in the ATPase
assay, and it was reported as 0.55 M in the bindingActivity of PU3 Analogs
We have synthesized a series of PU3 analogs (Figure 4) assay.
The cellular activity of compounds 1, 8, and 11 wasand determined the structures of the complex between
each of the compounds and Nt-HSP90. 1 is the original measured using a growth inhibition (GI) assay on the
Chemistry & Biology
780
For all compounds, the inhibitors induce upregulation
of HSP70, which is depleted over time. Although there
is some variability, compounds consistently induce
downregulation of CDK4 ErbB2, and Raf-1.These results
indicate that cell growth inhibition is occurring by a
mechanism dependent on HSP90 inhibition.
Structure-Activity Relationships of PU3 Analogs
A variety of molecular modeling calculations and analy-
ses can use the structures of the compounds bound to
the protein to rationalize the observed structure-activity
relationships (SAR) for not only the compounds in Figure
4, but also the activity reported for previously published
compounds by Chiosis et al. [10, 11].
Effect of Different Methoxy Substitution
on the Phenyl Ring
We analyzed the effect of different patterns of methoxy
group substitution on the trimethoxy phenyl ring group
of PU3. As expected for a region where ligand and pro-
tein are closely packed, the behavior that we have ob-
served is not additive. The measured activity is always
a result of the balance between different forces (internal
energy, hydrophobic interactions, polar interactions, in-
duced effects, shape complementarity, etc.) and, given
the complexity of the system, is often difficult to under-
stand without a careful analysis of the structure.
A compound with a single methoxy group at R3 is
more potent than the original trimethoxy compound (3,
IC50  76 M versus 1, IC50 
 200 M). This is somewhat
surprising, as the oxygen is not making any polar inter-
action and is buried in a hydrophobic cavity created by
Met98 and Val150. Even more intriguingly, the R4 single
methoxy compound is inactive (2, IC50 
 200 M), even
though the oxygen is interacting with a network of water-
mediated hydrogen bonds involving O of Tyr139, N1
of Trp162, and O of Leu103. Close inspection of the
structures of these compounds bound to Nt-HSP90
shows that the binding of 2 is penalized by the presence
of a void in the cavity, whereas 3 provides much better
shape complementarity and packing between receptorFigure 5. PU3 Ligands Elicit HSP90 Molecular Signature
and ligand.HCT116 cells were exposed to compounds 1, 8, and 11 at concentra-
tions of 100 M for 1 (2GI50) and 17 M for 8 and 16.5 M for 11 Figure 6A shows an overlay of the structures of 3
(5GI50) as described in the main text. Cell lysates obtained after and 2 together with the structures of PU3 and the 2,3-
8, 16, 24, 48, 72, or 96 hr incubation were subjected to Western blot methylenedioxy compound, 4. This emphasizes that the
determination of HSP70, Raf-1, CDK4, and ErbB2. 17AAG is included methyl groups of 3 and 2 are found in approximately theas a positive compound control, and protein loading was established
same position, making a close contact with the aromaticby GAPDH determination.
system of Trp162. 4 combines both methoxy features
in a five-membered ring. This compound combines the
human colon tumor cell line, HCT116, giving GI50 values good packing features of 3 with the water-mediated
of 50 M, 3.4 M, and 3.3 M, respectively. This com- hydrogen bonding of 2, making it one of the most active
pares well with the GI50 of 2 M reported by Chiosis et compounds within our PU3 series (IC50  14 M).
al. for 8 (compound 71 in [11]). Additional experiments This analysis suggests that methoxy groups at both
were also performed to measure the pattern of expres- positions R3 and R4 would be difficult to accommodate.
sion of proteins that are known to be affected by specific A comparison of the whole series of compounds (Figure
HSP90 inhibition [17]. Western blot assays were used 6B) emphasizes that the trimethoxy compounds adopt
to measure the upregulation of the chaperone HSP70 a slightly different conformation, with the methyl group
and downregulation of the HSP90 client proteins Raf-1, of the R4 methoxy pushed toward the hydrophilic envi-
CDK4, and ErbB2. This was measured at either twice ronment of the solvent channel, while the oxygen of the
(for compound 1 because of solubility limitations) or five R4 methoxy remains in the hydrophobic cavity. Thus,
times (for compounds 8 and 11) the GI50 required for cell although the methoxy at R2 provides a set of water-
growth inhibition. Figure 5 shows a series of Western mediated interactions, the other methoxy groups are in
blots showing the levels of different proteins present in unfavorable positions, giving rise to the relatively poor
activity seen for PU3.cells following exposure of compound to HCT116 cells.
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Figure 6. Comparison of PU3 Ligands
(A) Stereo figure showing the structure of four
compounds overlaid together with selected
amino acids (Trp 162, Met 98, Leu 107, Val
150, Phe 138, and Tyr 139) for a representa-
tive protein structure (with compound 2
bound). Nitrogens are blue, oxygens are red,
and sulphurs are yellow. For the protein, car-
bons are green, with the carbons of different
compounds colored as follows: purple is 1,
yellow is 4, and green are 2 and 3. A key water
molecule is shown as a sphere, absent in the
3 structure.
(B) The structure of the 12 featured PU3 ana-
logs bound to Nt-HSP90, overlaid on the
purine ring. Nitrogens are blue, oxygens are
red, and fluorine or chlorine are light green.
The carbons of the trimethoxy benzene-con-
taining compounds (1, 6, 7, and 8) are in pur-
ple, the carbons of the OCH2O bridged com-
pounds (4 and 12) are yellow, and the carbons
of the other compounds are pale green.
One outcome of this analysis was the design and ligand from steric clashes between Cl and the purine
ring. Quantum-mechanical (QM) calculations at B3LYP/synthesis of 5, which has methoxy groups at R2 and
R5. The addition of a methoxy group at R2 roughly dou- 6-31G(d) level of theory indicate that the conformation
observed in the crystal is 2.7 kcal/mol less stable inbles the potency (cf. IC50 41 M versus IC50 for 3 of 75
M), which can be explained by the formation of an vacuo than the conformation in which a rotation of 180
has been performed along the axis of the C10-C1	 bond.additional water-mediated hydrogen bond between the
methoxy group and N of Phe138. Choice of Linker between Purine
and Methoxy Phenyl GroupEffect of Substitutions at R2
Substitutions at R2 were investigated by Chiosis et al. Chiosis et al. [11] found that only –CH2– was suitable as
a linker between the purine and trimethoxy phenyl ring[11] with chlorine and bromine. Cl provides improved
activity, mono-Br is approximately as active as PU3, systems to give active compounds. The relative orienta-
tion and position of the purine binding site (Bergeratand di-Br is completely inactive. The structures of 7 and
8 show that the atom of chlorine participates in many fold) and the channel have tight constraints. Larger
groups (such as –O–CH2–) will result in a misplacementhydrophobic contacts with the side chains of Met98,
Phe138, Val150, and Val186. The packing of this atom is of the phenyl ring, while groups that could be conju-
gated, such as N, will drive the rings toward a coplanarextremely compact, particularly with Phe138 and Met98,
with the closest contacts being almost exactly the sum orientation, therefore penalizing the perpendicular con-
formation required to fit the binding site. Figure 6B em-of the van der Waals radii. These are very favorable
dispersion and hydrophobic interactions, with the calcu- phasizes the variation seen in the methoxy series of
structures, where the angle at the methylene bridgelated van der Waals term alone accounting for 2 kcal/
mol [18]. Both the bond distance and the van der Waals ranges from 110 (para-monomethoxy 2) to 120 (1-pen-
tyne trimethoxybenzyl 8). This conformational prefer-radii of bromine are larger than that of chlorine, sug-
gesting that the mono-bromine could only be accommo- ence has been analyzed through QM calculations at
B3LYP/6-31G(d) level of theory. These show that thedated by changes in conformation of the phenyl ring
and/or adjustments in the pocket, while the di-bromo angle of minimum energy is 115.5, and that all angles
between 110 and 120 are within 0.5 kcal/mol of thiscompound will not fit.
The increase in potency from the favorable interaction minimum. The QM calculations also indicate that the
observed dihedral angles φ1 (N9-C8-CH2-C1	, whichof Cl is essentially cancelled out by internal strain in the
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ranges from 58 to 81) and φ2 (C8-CH2-C1	-C2	, Binding of Purine Fragments
We have determined the structures of Nt-HSP90 crys-which ranges from 24 to 56) are preferred over
planar (φ1  180) or V-shaped conformations (φ2  tals soaked with 22 mM adenine and with N9-ethyl ade-
nine (data not shown). These structures show that the90). When the methylene bridge is replaced by oxygen,
the angle of minimum energy becomes 120.6, and fragments bind in the same position as seen for the
purine moieties of PU3 and ADP. In addition, the bindingsmaller torsions are heavily penalized (  110; H 
2.2 kcal/mol). In addition, the planar conformation is of these fragments to protein was monitored through
saturation transfer difference measurements using NMRpreferred over the perpendicular (φ1  180; φ2  0;
H  2.5 kcal/mol). This, we believe, explains why spectroscopy (see Experimental Procedures). No bind-
ing could be observed for 1 mM adenine binding to 10such substitution produces inactive compounds [11].
Substitution at C2 M Nt-HSP90 protein. However, binding could be seen
for N9-ethyl adenine, and this binding was displaced byThe purine ring of PU3 fits tightly into the ATP binding
pocket of the protein. It is therefore not surprising that addition of 100 M PU3. It is difficult to determine the
affinity of fragments seen in such NMR or X-ray experi-there is little scope for substitution of bulky or rigid
groups such as iodine, cyano, or vinyl at C2, primarily ments, as binding is influenced by many kinetic effects
(such as exchange kinetics or crystal lattice). However,because of the steric hindrance from the backbone of
Gly 97. However, fluorine at position C2 does provide the results suggest that N9-ethyl adenine is binding with
an affinity greater than 5–10 mM and that adenine iscompounds with increased potency. We have used mo-
lecular interaction potential calculations (MIP) [19] to binding with weaker affinity. This level of affinity is con-
sistent with the lack of activity seen for the Ad-But com-obtain an explanation for this effect, using 8,9-dimethyl-
adenine and 8,9-dimethyl,2-fluoro-adenine as models pound from Chiosis et al. [10]. These observations also
emphasize that although the core purine fragment bindsof PU3 analogs (results not shown). The comparison of
the potential shows that the fluorine atom polarizes the to the active site, much of the affinity of binding to HSP90
by the PU3 analogs comes from other portions of themolecule and increases the interaction potential of N1
and the exocyclic amine, enhancing the interaction with compounds.
Binding of Biotinylated PU3Asp93 and the crystallographic waters. In addition, the
negative charge density over the fluorine also increases The results presented above provide a satisfying ratio-
nale for the observed structure-activity relationships forthe dipole and contributes to the improved solubility
reported by Chiosis et al. [11]. the PU3 series of compounds. The binding of the ligand
to the protein locates the purine moiety in the expectedAlkyl Side Chain at N9
The structure of PU3-bound HSP90 shows that the first position, and the trimethoxyphenyl portion of the ligand
exploits the creation of a new pocket formed from aand second methylenes of the alkyl chain interact with
residues Leu107 and Met98 of HSP90, forming favorable region of the protein that is seen to be conformationally
flexible across a number of crystal structures. The rela-hydrophobic interactions. These molecular contacts are
important for binding, as shown by the poor inhibitory tive position and orientation of the purine and trimeth-
oxyphenyl groups and the environment of the newlyactivity of N9-unsubstituted compounds. The remainder
of the side chain is solvent exposed and does not appear formed cavity can be used to understand the change in
potency of most of the PU3 analogs synthesized to date.to make contact with the protein. As described above,
the N9 position is sterically hindered, which means that There remains, however, one compound whose bind-
ing cannot be understood from this structural work.groups too bulky or not flexible enough to be accommo-
dated in this restricted space will result in steric clashes Chiosis et al. generated an R4-biotinylated PU3, which
was demonstrated to bind to HSP90, TRAP1, and GRP94with the protein and/or the phenyl ring of PU3. In either
case, the consequence would be decreased activity. [10]. In principle, such a major extension at the R4 posi-
tion could be accommodated through the solvent-filledThis explains why all the 9-N-alkylated compounds de-
rived from secondary alcohols are inactive (compounds tunnel at the back of the trimethoxyphenyl cavity that
reaches out into the solvent (with reference to Figure29, 30, 31, 33, and 34 [11]), as are most of the compounds
substituted at the second carbon (compounds 28, 39, 1B, the tunnel is underneath the right-hand helix and on
the face of the central  sheet). We have made series40, 43, 44, and 45 [11]). The only exception is compound
16, which benefits from small substitutents (cyclopropyl of compounds with extensions at R4 (data not shown):
and methyl). none show enzyme inhibition below 200 M, and we
After the first two carbons, the cavity opens to bulk have not been able to obtain a crystal structure for any
solvent, allowing a wider range of groups. This explains of them.
the relatively flat SAR observed in this area, and, as can
be seen in Figure 6B, there is some flexibility in the
Significanceconformation of the alkyl chain. Nevertheless, some
compounds (particularly pentyne) are significantly more
The structures of the N-terminal domain of HSP90active than others, perhaps due to the ability of the
and HSP90 are essentially identical and show re-alkyne group to provide some hydrogen bonding capac-
markable plasticity in the loop region capping the ATPity. In the structures of 7 and 8, the alkyne group makes
binding site. This is exploited by the PU3 series ofan interaction with the carbonyl oxygen of Gly 135,
compounds, which induce the formation of a distinc-whereas a change in the conformation of the alkyl chain
tive pocket with the loop in a regular  helix. PU3-leaves the alkyne group pointing toward the acidic side
chain of Asp 102 in 11. based inhibitors with enhanced potency have been
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on ice for 1 hr prior to setting up the crystallization trays. The com-designed that elicit the expected molecular signature
pounds were synthesized as described in [12].for cellular activity for inhibition of HSP90 activity.
Structure DeterminationThese structural studies provide a detailed rationale
The crystals were frozen in the same way as the apo crystals. Data
for most of the observed changes in affinity, high- were collected for Nt-HSP90 complexed to compound 1 on a
lighting the conformational changes and molecular in- Mar345 image plate on a Rigaku/MSC rotating anode at the Univer-
sity of York and processed using DENZO. Although the complexteractions that can be exploited in the design of further
crystallized in the same space group as the apo protein, the unitimproved HSP90 inhibitors for assessment as antican-
cell parameters were nonisomorphous. The PU3-bound structurecer therapeutics.
was solved by molecular replacement with AMoRe [25] using the
apo HSP90 structure as the search model. All model building wasExperimental Procedures
carried out using the molecular graphics program O, and refinement
calculations were performed with REFMAC5. Following structureHSP90
solution, difference electron density maps were calculated for theProtein Production
initial model, the ligand structure was modeled into the differenceBoth the hexa-histidine-tagged and untagged N-terminal fragment
density peaks, and the coordinates were refined before final additionof HSP90 were overexpressed in the E. coli strain BL21 (P Lys S).
of solvent. The progress of the refinement was assessed using RfreeThe tag was added as an aid to purification, which, for the histidine-
and R factor, and the final structure was validated using PROCHECKtagged protein, was carried out using a Ni affinity column followed by
and the CCP4 package [26].a monoQ ion-exchange column. Untagged protein was expressed in
Essentially identical crystallization, data collection, and refine-the same way as the tagged protein, but this protein lysate was run
ment methods were used in the determination of the structure ofsolely on the monoQ column. Both protein samples were concen-
Nt-HSP90 in complex with each of the compounds listed in Figuretrated to approximately 20 mg ml1 using ultrafiltration into a final
4. All structures have been deposited in the Protein Data Bank withbuffer containing 20 mM TRIS (pH 7.4) and 0.5 M NaCl. Accurate
the codes shown in Figure 4, and the deposited files contain alldetermination of protein concentration was achieved using a Brad-
data and refinement statistics. In summary, the resolution of dataford assay.
collected for the complexes ranged from 1.9 A˚ to 2.6 A˚, and theCrystallization
structures were refined to Rfree/R factor values of between 20.4%/Initial conditions for crystallization of both hexa-histidine-tagged
17.2% and 21.4%/25.3%. Full data collection and refinement statis-and untagged Nt-HSP90 protein were found using commercial
tics are presented in the Supplemental Data.screens. Screening was carried out using the 24-well hanging-drop
vapor diffusion technique. Optimum conditions for both were found
to be in solutions #3 and #6 of Clear Strategy Screen number 1 HSP90 in Complex with PU3
obtained from Molecular Dimensions. Both of these conditions con- Expression, Purification, and Crystallization
tain 0.1 M Na Cacodylate (pH 6.5) and 25% PEG 2K MME. In addition, HSP90 1-234 with a N-terminal 6His tag was expressed in E. coli
solution #3 contains 0.2 M MgCl2 and solution #6 contains 0.8 M strain BL21-DE3. The protein was purified using a nickel-bound
NaFormate. The reservoir well contained 500 l of the precipitant HiTrap column and then a ResourceQ column. The 6His tag was
solution, and the hanging drops were formed by mixing 2 l of the removed by digestion with enterokinase, and the protein was repuri-
proteins with 2 l of the reservoir solution. The plates were left at fied on the ResourceQ column. Nt-HSP90 complexed with PU3
4C. Crystals appeared within a few hours and were of a suitable was crystallized in 25% PEG MME 2000, 0.1 M Na Cacodylate (pH
size for data collection, in some cases, after overnight growth. 6.5), 0.2 M MgCl2.
Structure Determination and Refinement Data Collection and Refinement
Crystals were transferred to cryoprotectant solution (crystallization Crystals diffracted to 2.45 A˚ on an Raxis4 image plate mounted on
reservoir solution with PEG concentration increased from 25% to a Rigaku MSC rotating anode source. The space group was the
35%), and data were collected to 1.42 A˚ and 1.65 A˚ resolution for same as the Nt-HSP90-PU3 crystal, I222, with cell dimensions of
untagged and hexa-histidine-tagged Nt-HSP90, respectively, at a  66.8 A˚, b  90.6 A˚, and c  96.2 A˚. A data set was collected
liquid N2 temperature at the ESRF, stations ID14eh2 and ID14eh4. from a single crystal, and the data were processed using Denzo
Diffraction data were processed using DENZO [20]. The N-terminal and scaled with Scalepack. Molecular replacement using AMoRe
domain fragment of apo HSP90 (both his tagged and untagged) within CCP4i used the native Nt-HSP90 structure as a model. Both
crystallizes in space group I222, with unit cell dimensions isomor- rigid body and restrained refinement using REFMAC5 within CCP4i
phous to those of the previously solved HSP90 N-terminal domain reduced the R factor and Rfree. Maps showed that PU3 was bound
fragment (PDB ID code 1YER). The structure was solved by isomor- and the conformation of the loop (residues 104–111) is the same
phous replacement using the 1YER model coordinates and the re- as that of the Nt-HSP90-PU3 structure. The residues that differ
finement program REFMAC5 [21]. Twenty cycles of rigid-body re- between the two structures were identifiable from the maps and
finement followed by 20 cycles of restrained refinement were carried rebuilt accordingly. The structure was refined to Rfree/R factor values
out. All model building was carried out using the molecular graphics of 29.4%/23.5% and has been deposited in the PDB with ID code
program O [22], and refinement calculations were performed by 1UYM. Full data collection and refinement statistics are presented
REFMAC5. Following structure solution, difference electron density in the Supplemental Data.
maps were calculated for the initial model and inspected. Crystallo-
graphic water molecules were added by cycling REFMAC with ARP
[23]. Following each round of refinement, the models were adjusted Assays
Malachite Green Assay for ATPase Activityand further solvent molecules were gradually added. The progress
of the refinement was assessed using Rfree and the conventional R The malachite green assay for determining HSP90 ATPase activity
has been described elsewhere [16]. Briefly, 0.42 mM yeast HSP90factor. Refinement converged at Rfree/R factor values of 22.1%/
18.3% and 22.7%/19.9% for the untagged and tagged protein. The is incubated overnight at 37C in assay buffer (100 mM Tris-HCl [pH
7.4], 150 mM NaCl, 6 m MgCl2) containing 370 M ATP with orfinal structures were validated using Procheck [24], and the un-
tagged structure was deposited in the Protein Data Bank with ID without test compound in DMSO (0.25%). The reaction is stopped
by the addition of malachite green reagent (0.95% ammonium mo-code 1UYL. Full data collection and refinement statistics are pre-
sented in the Supplemental Data available with this article online. lybdate [from 5.725% stock in 6 M HCl], 0.027% malachite green,
0.3875% polyvinyl alcohol) followed by sodium citrate (2.96%). The
absorbance is then determined at 620 nm.HSP90 in Complex with PU3 Analogs
Crystallization Cell Lines
Human colon cell lines, HCT116, were obtained from ATCC (Man-Crystals of the N-terminal HSP90-PU3 complex were grown in the
same conditions as the apo proteins, except 20 mM ligand solution assas, USA). and were grown as monolayers in Dulbecco’s modified
Eagle’s medium containing 10% fetal calf serum, 2 mM glutamine,was added to the protein solution, and the mixture was left to stand
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Accession Numbers
The structures of HSP90 described in this article have been depos-
ited in the Protein Data Bank with the following ID codes: 1UYL,
untagged HSP90 apo-structure; 1UYM, HSP90 complexed with
PU3 (compound 1); 1UY6, 1UY7, 1UY8, 1UY9, 1UYC, 1UYD, 1UYE,
1UYF, 1UYG, 1UYH, 1UYI, 1UYK, HSP90 complexed with com-
pounds 1 to 12 of Figure 4, respectively.
